13 July 2026
Baker McKenzie Advises Chemomab on Merger with Scipher Medicine
Advising firms
Deal team
8 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Michal Berkner Lead | Baker McKenzie | Partner | Corporate M&A | Not stated |
| Per Chilstrom | Baker McKenzie | Partner | Corporate | New York |
| Ross Staine | Baker McKenzie | Partner | Tax | Houston |
| Kimberly Franko | Baker McKenzie | Partner | Employment | New York |
| Christopher Guldberg | Baker McKenzie | Partner | Employment | Chicago |
| Zach Bassen | Baker McKenzie | Associate | Not stated | New York |
| Alejandra Cuadra | Baker McKenzie | Associate | Not stated | New York |
| Matt Bratovich | Baker McKenzie | Associate | Not stated | New York |
5 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 150m (USD 150 million)
- What the figure measures
- Enterprise value
- Client
- Chemomab Therapeutics Ltd.Target
- Counterparties
- Scipher Medicine Corporation (Buy-side)